BOMRA: New Medicines Law Consultation on 2025 Act Begins

• The Botswana Medicines Regulatory Authority (BOMRA) is seeking public feedback on the draft regulations under the Medicines and Related Substances Act, 2025.
• BOMRA CEO Dr. Seima Dijeng urged pharmaceutical executives, medical device manufacturers, and industry lawyers to provide "blunt" input.
• This legislation represents the most significant overhaul of Botswana's pharmaceutical regulatory framework.
• The consultation is for the draft regulations under the enacted Medicines and Related Substances Act, 2025.

For legal practitioners advising companies within Botswana's pharmaceutical and medical device industries, this BOMRA consultation on the draft regulations under the Medicines and Related Substances Act, 2025, represents a critical window of opportunity to influence future regulatory direction.

The Botswana Medicines Regulatory Authority (BOMRA) has initiated a crucial public feedback process concerning the Medicines and Related Substances Act, 2025, and its accompanying draft regulations, signaling a significant moment for the nation's healthcare sector. Dr. Seima Dijeng, the Chief Executive Officer of BOMRA, recently addressed a gathering of key stakeholders, including pharmaceutical executives, medical device manufacturers, and legal professionals specializing in the industry, to solicit their candid input on the recently enacted Medicines and Related Substances Act, 2025, and its draft regulations.

During his address on Wednesday, Dr. Dijeng made a direct and unambiguous appeal for honesty and transparency, urging attendees to "be blunt" in their assessments and recommendations. He clarified that the authority was not presenting a finalized piece of legislation but rather the Medicines and Related Substances Act, 2025, and its accompanying draft regulations. This open and collaborative approach underscores BOMRA's commitment to developing regulations that are both effective and reflective of industry realities. The BOMRA consultation on the draft regulations under the Medicines and Related Substances Act, 2025, is therefore positioned as a foundational step in a broader reform effort.

This initiative marks the most substantial revision of Botswana's pharmaceutical regulatory framework to date, promising a transformative impact on how medicines and medical devices are controlled within the country. The Medicines and Related Substances Act, 2025, is poised to introduce significant changes across the entire spectrum of drug control and medical device oversight, reflecting a proactive move by BOMRA to modernize and strengthen the existing regulatory landscape. This Botswana pharmaceutical regulatory overhaul aims to enhance public health and safety standards.

The comprehensive nature of this overhaul suggests that virtually every aspect of the pharmaceutical and medical device sectors will be impacted. From product registration and manufacturing standards to distribution, advertising, and post-market surveillance, the new legislation aims to create a more robust, efficient, and internationally aligned system. The Medicines and Related Substances Act, 2025, is expected to streamline processes while simultaneously elevating the quality and safety benchmarks for all regulated products.

For legal practitioners advising companies within Botswana's pharmaceutical and medical device industries, this BOMRA consultation on the draft regulations under the Medicines and Related Substances Act, 2025, represents a critical window of opportunity to influence future regulatory direction. The call for BOMRA public feedback on the draft regulations under the Medicines and Related Substances Act, 2025, provides a direct channel for industry lawyers to contribute to the shaping of future regulations, ensuring that the final legislation is both effective in its public health mandate and practical for businesses operating in the sector. Engaging early can help mitigate potential compliance challenges down the line.

Understanding the nuances of the Medicines and Related Substances Act, 2025, and proactively preparing clients for the impending medical device regulation changes under the Medicines and Related Substances Act, 2025, will be paramount. Lawyers should encourage their clients to actively participate in this pharmaceutical industry consultation on the draft regulations under the Medicines and Related Substances Act, 2025, leveraging Dr. Seima Dijeng's explicit invitation for frank discussion to advocate for their interests and help refine the regulatory environment. The outcome of this process will profoundly influence operational strategies, investment decisions, and compliance requirements for pharmaceutical and medical device companies in Botswana for years to come, making informed input now invaluable.

Lawyers advising pharmaceutical and medical device companies in Botswana should note this consultation period as a critical opportunity to provide input on the proposed "sweeping new medicines law" and prepare clients for significant upcoming regulatory changes to the country's pharmaceutical framework.

Source: Original reporting via Weekend Post